» Articles » PMID: 24362411

Short-term Combined Treatment with Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women with Polycystic Ovary Syndrome and Previous Poor Response to Metformin

Overview
Specialty Endocrinology
Date 2013 Dec 24
PMID 24362411
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.

Methods: A total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.

Results: Thirty six patients (aged 31.3 ± 7.1 years, BMI 37.1 ± 4.6 kg/m²) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5 ± 2.8 kg compared with a 3.8 ± 3.7 kg loss in the LIRA group and a 1.2 ± 1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4 ± 1.0 in the COMBI arm compared with 1.3 ± 1.3 in LIRA and 0.5 ± 0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5 ± 3.8 cm in the COMBI arm compared with 3.2 ± 2.9 cm in LIRA and 1.6 ± 2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.

Conclusions: Short-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.

Citing Articles

The Potential Role of Glucagon-Like Peptide-1 (GLP-1) Agonists for Polycystic Ovary Syndrome.

Rahim S, Pergolizzi Jr J Cureus. 2025; 17(1):e77998.

PMID: 40007927 PMC: 11852098. DOI: 10.7759/cureus.77998.


Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a Network Meta-Analysis of Randomized controlled trials.

Bo Y, Zhao J, Liu C, Yu T BMC Womens Health. 2025; 25(1):64.

PMID: 39955537 PMC: 11829492. DOI: 10.1186/s12905-025-03594-6.


Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis.

Zhao Y, Jiang L, Li N, Cao J, Pi J Reprod Sci. 2025; .

PMID: 39881036 DOI: 10.1007/s43032-025-01788-9.


Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome.

Akel M, Ziq A, Kaldas P, Hamden J, Omari A, Silanee A Cureus. 2024; 16(11):e73687.

PMID: 39677183 PMC: 11646169. DOI: 10.7759/cureus.73687.


Comparative Effectiveness of Antidiabetic Drugs as an Additional Therapy to Metformin in Women with Polycystic Ovary Syndrome: A Systematic Review of Metabolic Approaches.

Heidarpour M, Mojarad M, Mazaheri-Tehrani S, Kachuei A, Najimi A, Shafie D Int J Endocrinol. 2024; 2024:9900213.

PMID: 38500709 PMC: 10948218. DOI: 10.1155/2024/9900213.


References
1.
Maida A, Lamont B, Cao X, Drucker D . Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia. 2010; 54(2):339-49. DOI: 10.1007/s00125-010-1937-z. View

2.
Hedblad B, Nilsson P, Janzon L, Berglund G . Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med. 2000; 17(4):299-307. DOI: 10.1046/j.1464-5491.2000.00280.x. View

3.
Harborne L, Sattar N, Norman J, Fleming R . Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005; 90(8):4593-8. DOI: 10.1210/jc.2004-2283. View

4.
Lord J, Flight I, Norman R . Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ. 2003; 327(7421):951-3. PMC: 259161. DOI: 10.1136/bmj.327.7421.951. View

5.
Hu W, Li L, Yang M, Luo X, Ran W, Liu D . Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and liraglutide in humans. J Clin Endocrinol Metab. 2012; 98(1):290-8. DOI: 10.1210/jc.2012-2466. View